How EU GMP Annex 1 Is Reshaping Pharma Manufacturing

What Is EU GMP Annex 1?

EU GMP Annex 1 (2023) is a Good Manufacturing Practice (GMP)guideline issued under EudraLex Volume 4 by the European Commission that is dedicated to the manufacture of sterile medicinal products for human and veterinary use.¹

It details the requirements for manufacturing sterile pharmaceutical products intended for distribution in the European Union, with the goal of reducing contamination risk in finished injectable drug products and provides detailed guidance on contamination prevention, RTU component management, sterility maintenance, and controlling cleanroom control throughout manufacturing workflows.^{1,2, 11}

What challenges do drug manufacturers face conforming to EU GMP Annex 1?

Sterile drug manufacturers are challenged by Annex 1 implementation because it requires a fundamental shift from traditional cleanroom and testing‑based sterility assurance to integrated, design‑driven, digitally monitored contamination control across facilities, processes, and container‑closure systems—often within legacy plants not built for these expectations. ^1,2,4

While sterile drug manufacturers broadly agree with the intent of EU GMP Annex 1, implementing its much stricter sterility assurance expectations is genuinely difficult—especially when it drives significant changes and costs associated with facility design, automation, airflow, digital monitoring, and container‑closure control.

This is because most sterile manufacturing facilities were designed 10–30 years ago around cleanroom segregation and manual interventions, rather than the end-to-end contamination prevention, with minimal open product exposure, and tighter lifecycle risk control now expected under EU GMP Annex 1. As a result, existing cleanroom layouts often struggle to support robust unidirectional airflow and critical zone protection, and retrofitting isolators or revised airflow into legacy spaces commonly introduces ceiling height constraints, HVAC rebalancing challenges, and conflicts between airflow integrity and operator access.

Historically, container‑closure components such as vials, stoppers, and seals were qualified in isolation and managed largely through supplier oversight and incoming QC, but EU GMP Annex 1 now treats them as critical contamination control elements requiring clear, end‑to‑end linkage from component preparation through filling, stoppering, sealing, and post‑fill sterility maintenance. This shift creates challenges in demonstrating sterility across component interfaces, closing data gaps between suppliers and fill‑finish operations, and justifying robust, lifecycle container closure integrity testing (CCIT) using deterministic, risk‑based methods—particularly for legacy products not originally validated to modern Annex 1 expectations. This places greater value on RTU packaging components with demonstrated CCI performance across relevant production, storage, and transport conditions.

These risks are amplified for advanced therapies and injectable biologics that cannot undergo terminal sterilization after packaging, leaving no opportunity to eliminate contamination at the final stage. Consequently, sterility assurance depends entirely on robust aseptic processing, the use of reliably sterile RTU components, and tight, end-to-end contamination control measures as defined by EU GMP Annex 1.^1,5

Key Changes That Impact Pharma Drug Manufacturers

Contamination Control Strategy (CCS)

Under the revised EU GMP Annex 1, regulators have introduced significantly stricter and more harmonized expectations—aligned with principles applied by other major authorities such as the US Food and Drug Association (FDA) and Pharmaceuticals and Medical Devices Agency (PMDA)—around how sterile manufacturing operations are designed, monitored, documented, and controlled. Central to these expectations is the formal requirement for a documented Contamination Control Strategy (CCS), which serves as the framework for managing risks associated with personnel, processes, materials, equipment, and the manufacturing environment throughout the sterile product lifecycle. ^1,2,6

Drug manufacturers are now expected to proactively identify all potential sources of microbial, particulate, and endotoxin contamination that could impact sterile APIs and drug products, demonstrate that these risks are well understood, and show—using a structured, science- and risk-based approach—how they are effectively controlled. This includes explicit identification of sterility breach risks within the filling environment and clear justification of the mitigations applied. ^1,6,8

Within this framework, ready‑to‑use (RTU) packaging components have become a strategic tool rather than a tactical convenience, as they directly address several of the highest‑risk contamination pathways identified in the CCS. By minimizing component handling, eliminating in‑house washing and sterilization steps, and providing validated sterility and low endotoxin assurance, RTU vials, stoppers, and seals reduce the overall contamination risk burden within the fill‑finish environment. For manufacturers facing tighter EU GMP Annex 1 scrutiny—particularly for aseptically processed products and non‑terminally sterilized biologics—RTU components simplify CCS justification, strengthen sterility assurance, and support more robust container‑closure integrity throughout filling, storage, and distribution.

As a result, many organizations are increasingly relying on suppliers that provide ready-to-use (RTU) packaging components to reduce handling, limit contamination risks, and support compliance with Annex 1 CCS requirements

Quality Risk Management (QRM) & PQS

Under EU GMP Annex 1, sterile drug manufacturers are expected to manage sterility assurance through an integrated application of Quality Risk Management (QRM) and the Pharmaceutical Quality System (PQS). QRM provides the structured methodology for identifying, assessing, and mitigating risks to product sterility, while the PQS ensures these risk controls are consistently implemented, monitored, and continually improved across the entire product lifecycle. Together, they move sterility assurance away from reactive testing and toward proactive, design-based control embedded directly into operations.^1,6,8

Within this framework, EU GMP Annex 1 explicitly requires manufacturers to understand and manage the interaction between facility design, operating procedures, environmental and process monitoring, and material flows—supported by routine review and documented evidence of ongoing control and training. Personnel responsible for batch release must have full visibility of these controls, access to complete records, and sufficient knowledge to make risk‑based decisions, reinforcing accountability throughout the organization.^{1,6, 11}

Given the critical impact of primary packaging on sterility assurance, regulators now expect packaging components and containment systems to be fully integrated into the CCS through QRM and PQS processes. This includes risk-based supplier qualification, validated cleaning and sterilization processes, and controlled transfer of components into the aseptic environment. In this context, RTU vials, stoppers, and seals offer strategic value by reducing in-house processing complexity, eliminating high-risk preparation steps, and providing pre-validated sterility and endotoxin control—thereby simplifying QRM rationales, strengthening PQS execution, and supporting a demonstrable state of control under Annex 1 expectations.^1,3,6,9

By sourcing packaging components that arrive with supplier-owned, validated cleaning/sterilization, endotoxin control, and documented release evidence, manufacturers shift a meaningful portion of high-risk, failure-prone unit operations (washing, depyrogenation, sterilization, and handling) away from the fill-finish site and into a controlled, specialized process environment. This does not reduce the manufacturer’s accountability; it requires robust supplier qualification, oversight, and change control.

It reduces the number of contamination pathways that must be controlled in-house, and strengthens the manufacturer’s ability to demonstrate a defensible, end-to-end state of control during inspection.

Stricter Requirements for Primary Packaging and Containers

While EU GMP Annex 1 does not mandate the geographic origin of ready-to-use (RTU) primary packaging components, it places heightened regulatory emphasis on how those components are cleaned, depyrogenated, sterilized, protected, and introduced into the aseptic environment. The revised guideline reinforces expectations for validated cleaning, endotoxin reduction, and sterilization processes, and strongly encourages the use of modern barrier technologies—such as isolators, RABS, and automated or robotic handling—to minimize contamination risks during component transfer and fill & finish handling. This reflects a broader Annex 1 shift away from reliance on operator technique toward engineered, reproducible controls for high-risk materials entering Grade A zones.^1,3,4,10

Annex 1 explicitly recognizes primary packaging containers and components as significant contamination risk vectors, requiring systematic identification and control of microbial, particulate, chemical, and cross-contamination hazards across aseptic operations. Manufacturers must now demonstrate that packaging components are cleaned using validated processes, supported by complete sterilization records for every cycle, and that sterility is effectively maintained through transfer into higher-grade environments. Where RTU components arrive sterilized in sealed multi-layer sterile barrier systems, handled by validated transfer methods—such as airlocks or pass-through hatches—and undergo external packaging disinfection allowing for non-cleanroom storage and shown to support effective, stepwise decontamination during material ingress.

In practice, these requirements reinforce the strategic value of RTU components as a sterility-risk control and risk-transfer mechanism under Annex 1. By sourcing components with pre-validated cleaning, depyrogenation, sterilization, and sterile barrier designs, manufacturers shift some of the most sensitive and failure-prone contamination controls into specialized supplier processes. This reduces in-facility processing steps, limits aseptic handling and transfers, simplifies justification within the CCS, and strengthens the manufacturer’s ability to demonstrate controlled, reproducible sterility assurance and container protection during regulatory inspection—particularly in highly automated, barrier-based filling environments.

Upstream Impact: Bulk Manufacturing, Storage, and Transport

How DURAN PURE Bottles Address Upstream Compliance

Under EU GMP Annex 1, drug manufacturers are expected to assess the suitability of primary packaging not only at the point of filling, but across the entire process workflow and product lifecycle. This includes demonstrable understanding of extractables and leachables (E&L) profiles, as well as the ability of the container closure system to maintain integrity during sterilization, transport, storage, and downstream use. For sterile APIs, biologics, and injectable intermediates, Annex 1 reinforces that upstream packaging choices directly influence overall sterility assurance and CCS defensibility.

From an E&L standpoint, DURAN® PURE bottles are inherently well suited for sterile pharmaceutical and bioprocessing applications. Manufactured from Type I borosilicate glass, DURAN® bottles contain no organic additives, exhibit extremely low elemental release, and demonstrate high hydrolytic and chemical resistance under common sterilization and long-term storage conditions. These intrinsic material properties reduce the risk of interaction with sensitive drug substances and simplify E&L risk assessments within Annex 1-driven QRM frameworks.

Beyond material composition, DURAN® PURE bottles and compatible pharmaceutical-grade closures are designed for GMP-compliant production and controlled bioprocessing workflows, supporting their use for in-process storage, intermediate transfer, and finished drug product containment. When paired with an appropriate closure system, these containers align with Annex 1 expectations by enabling traceability, particulate and endotoxin control, supported certification, and demonstrable container-closure integrity (CCI) performance.^1,3,9

DURAN® PURE bottles help address Annex 1 compliance upstream by reducing variability and contamination risk before aseptic filling even begins. Functioning as a risk‑containment boundary upstream of fill‑finish—preserving product quality and containment integrity during holds and transfers, so fewer contamination and E&L risks are “imported” into the aseptic core. This strengthens the CCS by controlling risk earlier, where interventions are less complex and more reproducible.

Downstream Impact: Fill/Finish Operations – Consequential Shift

Wheaton Vials for EU GMP Annex 1-Compliant Fill/Finish

As Annex 1 extends sterility assurance expectations beyond the fill step and into the full lifecycle of component handling, the pressure on fill-finish operations has shifted toward reducing what enters the aseptic core in the first place. For manufacturers, this has translated into a clear downstream preference for primary containers that arrive with sterility and cleanliness already established, rather than being created through multiple in-house preparation steps. ^1,4

Wheaton™ ready-to-use (RTU) vials inclusive of Wheaton® CompletePAK vials from DWK Life Sciences address this shift by removing a foundational source of fill-finish contamination risk. Supplied pre-washed and sterilized using validated processes, RTU and Wheaton® CompletePAK vials eliminate the need for on-site washing, depyrogenation, and sterilization—steps that Annex 1 increasingly recognizes as avoidable contributors to particulate, microbial, and endotoxin exposure. By minimizing handling and simplifying transfer into isolators, RABS, or Grade A environments, these vials support more stable airflow conditions, fewer interventions, and more reproducible contamination control at the point of fill.

From a CCS perspective, RTU and Wheaton® CompletePAK vials function as a downstream risk-reduction mechanism, narrowing the number of critical operations that must be controlled within the aseptic core. This allows manufacturers to concentrate internal controls on the remaining high-value steps—aseptic filling, stoppering, sealing, and verification of container closure integrity (CCI)—while strengthening the overall sterility assurance case expected under Annex 1 inspection.

This RTU-driven downstream strategy is consistent with other vial platforms widely adopted in EU GMP Annex 1 environments, including nested RTU formats such as Stevanato Group EZ-fill® vials. EZ-fill® vials are supplied as pre-washed, depyrogenated and sterilized vials in a nest & tub configuration designed for controlled, repeatable introduction into robotic isolators or RABS with minimal direct handling. This helps injectable drug manufacturers protect first‑air conditions at the point of fill. Within the CCS framework, this approach provides an industry standard RTU secondary packaging format enabling full isolation process controls.

Bridging the Gap: DWK High-Value Services

Across upstream processing, component preparation, and downstream fill-finish operations, EU GMP Annex 1 has shifted expectations toward integrated, end-to-end sterility assurance supported by documented, risk-based controls. DWK Life Sciences’ high-value services are designed to bridge these stages by simplifying workflows, reducing sourcing and compliance complexity, and enabling manufacturers to operationalize Annex 1 requirements alongside international standards and customer-specific quality expectations. ^1,7

Central to this approach is DWK’s portfolio of ready-to-use (RTU), CompletePAK®, and EZ-fill® vials, which enable direct and controlled transfer into aseptic filling environments while reducing manual handling, on-site preparation steps, and contamination risk. DWK RTU offerings span both small-batch and large-scale manufacturing needs, at bench to RABS and robotic isolator operations, and are supported by validated particulate cleaning, depyrogenation, sterilization, and, where required, siliconization processes. RTU components are delivered with full Certificates of Analysis or Conformance, complete traceability, and comprehensive validation documentation, and are managed within formal deviation and change-control systems—providing manufacturers with the documented evidence expected under PQS and CCS review.

DWK supports multiple terminal sterilization decontamination approaches—including steam, irradiation, and vaporized hydrogen peroxide (VHP)-based systems where appropriate to component type and packaging design —allowing alignment with a wide range of product sensitivities and facility designs. Custom secondary packaging configurations such as EZ-fill® nest-and-tub systems, EZ-fill® partitioned trays, and bulk RTU vial trays, together with RTU closures supplied in single-use pouches or ported bags, enable validated, stepwise ingress into isolators or RABS while preserving sterile barrier integrity during transfer.

Taken together, DWK’s RTU vial and closure systems support Annex 1’s shift toward contamination prevention by design, combining sterile barrier packaging with defined, validated approaches to material ingress and aseptic presentation. This reduces the number of contamination pathways created by on-site component preparation and provides a clearer, more defensible line of evidence—from sterilization records and packaging integrity, through transfer validation, to container closure integrity (CCI) performance after stoppering and sealing. In this way, DWK RTU components function not merely as a convenience, but as input controls that strengthen the CCS and help sustain a demonstrable state of control under heightened Annex 1 scrutiny. ^1,7

Consistent with this strategy, Wheaton™ RTU and CompletePAK® and DWK EZ-fill® vials further reinforce Annex 1-compliant fill-finish operations by shifting key contamination risks out of the aseptic core, reducing human intervention, and strengthening the end-to-end sterility assurance narrative at the point where regulatory expectations are highest.

DWK can support an Annex 1 readiness discussion focused on your specific process and facility design—mapping critical contamination pathways, clarifying component transfer and barrier strategies, aligning documentation packages to CCS/QRM needs, and identifying where RTU components and upstream containment solutions can most effectively reduce risk and strengthen inspection defensibility.

References

1. EU GMP Annex 1 – Manufacture of Sterile Medicinal Products European Commission, EudraLex Volume 4 (rev. effective Aug 25, 2023)
2. PIC/S PE 009 – Guide to Good Manufacturing Practice for Medicinal Products Pharmaceutical Inspection Co‑operation Scheme (PIC/S)
3. USP <788>, <85>, <1207> – Particulates, Endotoxins, Container‑Closure Integrity
4. ISPE Baseline® Guide – Sterile Manufacturing Facilities
5. FDA Guidance: Sterile Drug Products Produced by Aseptic Processing
6. ICH Q9(R1) – Quality Risk Management (2023 revision)
7. EMA / PIC/S Inspection Observations on RTU Components and Aseptic Transfers
8. ICH Q10 – Pharmaceutical Quality System
9. ISO 15378 – GMP for Primary Packaging Materials
10. EU Annex 1 Sections 4, 5, 8 & 9 – Barrier Systems, Robotics, and Automation
11. Outsourced Pharma – EU Annex 1 in Practice (Feb, 13, 2026)

Why reusables matter: single‑use impact is mostly ‘make new again’